Pfizer BioNTech Vaccine Induces Immune Response In Early Phase Trial

A Covid-19 vaccine candidate co-developed by the pharmaceutical giant Pfizer and the German biotech firm BioNTech induces a “robust” immune response in healthy adults aged 18–55 years, according to an interim report of an early phase clinical trial, published in Nature on Wednesday. Researchers noted that BNT162b1 is an RNA vaccine that elicits an immune response by mimicking the mRNA molecule used by the novel coronavirus Sars-CoV-2 to build its infectious proteins. According to the study the vaccine candidate is delivered intramuscularly, and enables human cells to produce proteins part of the SARS-CoV-2 receptor-binding domain, against which the immune system is trained to produce antibodies. In the ongoing trial, the scientists assessed the safety, side effects, and safe dose of the vaccine candidate in 45 healthy adults. agencies

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!